The Experts below are selected from a list of 21186 Experts worldwide ranked by ideXlab platform
Katharine E. H. Thomas - One of the best experts on this subject based on the ideXlab platform.
-
Quality of life for non-small cell lung cancer patients in the age of immunotherapy.
Translational lung cancer research, 2018Co-Authors: Robert A. Ramirez, Katharine E. H. ThomasAbstract:Non-small cell lung cancer (NSCLC) is a very common and devastating disease that is accompanied by a range of symptoms. Patients can experience symptoms specific to their disease process (such as cough or dyspnea) or more generalized symptoms (such as fatigue and Loss of Appetite).
Aminah Jatoi - One of the best experts on this subject based on the ideXlab platform.
-
Anorexia and Cachexia
2015Co-Authors: Aminah JatoiAbstract:Many patients with advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. In defining these terms a bit further, anorexia is associated with a marked Loss of Appetite and/or an aversion to food.
-
Pharmacological options for advanced cancer patients with Loss of Appetite and weight.
Expert opinion on pharmacotherapy, 2007Co-Authors: Deepti Behl, Aminah JatoiAbstract:The majority of patients with advanced cancer suffers from Loss of Appetite and Loss of weight at some point during their disease course. This sign and this sympton herald an early demise. However, no therapeutic intervention, apart from effective antineoplastic therapy, has been able to reverse this syndrome totally, and, in turn, to reverse this prognostic effect. Most clinical trials have focused largely on palliating symptoms, and, to this end, progestational agents and corticosteroids have proven to be the most effective in terms of improving Appetite. This article reviews data to support the use of these agents, discusses the findings of other more recent studies in this field and provides an overview of promising strategies that merit further investigation.
-
Current management of cancer-associated anorexia and weight Loss.
Oncology (Williston Park N.Y.), 2001Co-Authors: Aminah Jatoi, Charles L. LoprinziAbstract:Loss of Appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients—specifically, perioperative, severely malnourished cancer patients, stem cell and
Robert A. Ramirez - One of the best experts on this subject based on the ideXlab platform.
-
Quality of life for non-small cell lung cancer patients in the age of immunotherapy.
Translational lung cancer research, 2018Co-Authors: Robert A. Ramirez, Katharine E. H. ThomasAbstract:Non-small cell lung cancer (NSCLC) is a very common and devastating disease that is accompanied by a range of symptoms. Patients can experience symptoms specific to their disease process (such as cough or dyspnea) or more generalized symptoms (such as fatigue and Loss of Appetite).
Carlo Deangelis - One of the best experts on this subject based on the ideXlab platform.
-
Re-analysis of symptom clusters in advanced cancer patients attending a palliative outpatient radiotherapy clinic
Annals of palliative medicine, 2018Co-Authors: Erin Mckenzie, Liying Zhang, Pearl Zaki, Stephanie Chan, Vithusha Ganesh, Yasmeen Razvi, May Tsao, Elizabeth Barnes, Matthew K Hwang, Carlo DeangelisAbstract:Background: Cancer patients often present with several concurrent symptoms. There is evidence to suggest that related symptoms can cluster together in stable groups. The present study sought to identify symptom clusters in advanced cancer patients using the Edmonton Symptom Assessment System (ESAS) in a palliative outpatient radiotherapy clinic. Methods: Principal component analysis (PCA), exploratory factor analysis (EFA), and hierarchical cluster analysis (HCA) were used to identify symptom clusters among the 9 ESAS items using ESAS scores from each patient’s first visit. Results: PCA identified three symptom clusters (cluster 1: depression, anxiety; cluster 2: nausea, dyspnea, Loss of Appetite; cluster 3: pain, well-being, tiredness, drowsiness). EFA identified two clusters (cluster 1: tiredness, drowsiness, Loss of Appetite, well-being, pain, nausea, dyspnea; cluster 2: depression, anxiety). HCA identified three symptom clusters (cluster 1: depression, anxiety, pain, well-being; cluster 2: tiredness, drowsiness, dyspnea; cluster 3: nausea, Loss of Appetite). Conclusions: Symptom clusters were identified using three analytical methods. The following items were always in the same cluster: depression and anxiety; nausea and Appetite Loss; well-being and pain; tiredness and drowsiness. Further research in symptom clusters is necessary to advance our understanding of the complex symptom interactions in advanced cancer patients and to determine the most clinically relevant symptom clusters.
Oscar Arrieta - One of the best experts on this subject based on the ideXlab platform.
-
effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non small cell lung cancer randomised trial
Clinical Nutrition, 2014Co-Authors: Karla Sanchezlara, Jenny Turcott, Eva Juarezhernandez, Carolina Nunezvalencia, Geraldine Villanueva, Patricia Guevara, Martha De La Torrevallejo, Alejandro Mohar, Oscar ArrietaAbstract:Summary Background Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects. Objective To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients. Design Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated. Results Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy ( p p p = 0.01). Fatigue, Loss of Appetite and neuropathy decreased in the ONS-EPA group ( p ≤ 0.05). There was no difference in response rate or overall survival between groups. Conclusion Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, Loss of Appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).
